Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment

Buti M., Izumi N., Lim Y., Janssen H., Kao J., Streinu-Cercel A., ...Daha Fazla

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70 identifier